DIJON, France – 25 March 2026 (07:20 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, currently in the advanced stages of development and registration of ZEPIZURE®, an injectable for the management of epileptic seizures, today publishes its financial results for the financial year ended 31 December 2025. Continued progress on the industrial and regulatory priorities for ZEPIZURE®. Stronger support from BARDA, with total funding increased to $43.3 million. Development of the ZENEO® platform, notably for intramuscular administration, ZEPIZURE® Junior. Operating revenue up 12.25% to €14.9 million. Operating result improved to -€11.6 million (vs -€13.0 million published in 2024 and -€14.2...

HALIFAX, Nova Scotia, March 24, 2026 (GLOBE NEWSWIRE) — Highlights:Completed construction at the high-grade Bayan Khundii Gold Mine in Q3 2025 Produced first gold in September 2025 and sold 7,434 ounces gold at average price of US$4,187, for US$31M in gross project revenues including silver by-product in 2025 Announced updated independent mineral resource estimate for Zuun Mod molybdenum-copper porphyry project and initiation of preliminary economic assessment Entered option agreement to acquire up to 80% of the Tereg Uul Copper-Gold Project Conducted exploration programs at Bayan Khundii (Dark Horse), Zuun Mod molybdenum, Khuvyn Khar copper and Tereg UulErdene Resource Development Corp. (TSX:ERD; MSE:ERDN; OTCQX: ERDCF) (“Erdene” or the “Company”) is pleased to announce operating and financial results...

VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) — Skeena Resources Limited (TSX: SKE, NYSE: SKE) (“Skeena Gold & Silver”, “Skeena” or the “Company”) reports its fourth quarter and annual financial results for the year ended December 31, 2025. The financial statements, management’s discussion and analysis (“MD&A”), and annual information form (“AIF”) are available on Skeena’s website and have been posted under the Company’s profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov.        About Skeena Skeena is a leading precious metals development company focused on advancing the Eskay Creek Gold-Silver Project in British Columbia’s Golden Triangle. With the Project fully permitted and under construction, the Company is progressing Eskay Creek towards initial production and cash flow in the second quarter...

HOUSTON, March 24, 2026 (GLOBE NEWSWIRE) — Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported financial results for the fourth quarter and full-year ended December 31, 2025. Full Year and Q4 2025 Highlights:Epsilon – Full-Year 2025 & Q4 2025        2025 2024 Q4 2025 Q3 2025 YoY% QoQ%NRI Production              Gas MMcf 10,001 6,142 2,373 2,136 63 % 11 %Oil MBbl 223 187 94 39 20 % 138 %NGL MBbl 81 69 43 14 17 % 211 %Total MMcfe 11,825 7,676 3,196 2,456 54 % 30 %Daily MMcfe/d 32.4 21.0 34.7 26.7                   Revenues $M            Gas   29,121 10,786 6,839 4,758 170 % 44 %Oil   13,804 13,731 5,299 2,511 1 % 111 %NGL   1,979 1,482 1,180 267 34 % 342 %Midstream1   6,684 5,524 1,501 1,445 21 % 4 %Total   51,588 31,523 14,818 8,981 64 % 65 %               Realized...

Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter and full year ended December 31, 2025. “Over the past year, we advanced ABS-201 from preclinical...

Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026 Completed 52-week follow-up from Phase II trial COVALENT-112 (icovamenib in type 1 diabetes) with data expected in the second quarter of 2026 Initiated Phase I trial enrollment of GLP-131 (BMF-650 in obesity) with initial 28-day weight reduction data expected in the second quarter of 2026 Projected cash runway into the first quarter of 2027SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the full year ended December 31, 2025, and provided a business update. “The past year was a year of execution...

COLUMBUS, Ohio, March 24, 2026 (GLOBE NEWSWIRE) — Worthington Enterprises Inc. (NYSE: WOR), a designer and manufacturer of market-leading building and consumer products that improve everyday life by elevating spaces and experiences, today reported results for its fiscal 2026 third quarter ended February 28, 2026. Recent Developments and Third Quarter Highlights (all comparisons to the third quarter of fiscal 2025):Net sales were $378.7 million, an increase of 24%. Net earnings increased 15% to $45.1 million, while adjusted net earnings increased 7% to $48.5 million and adjusted EBITDA grew 15% to $84.6 million. Earnings per share on a fully-diluted basis (“EPS – diluted”) improved to $0.92 from $0.79 per share, while adjusted EPS – diluted increased to $0.98 from $0.91 per share. Operating cash flow increased 8% to $61.9 million,...

OverviewFull Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 Million Cash Rose to $15.4 Million at December 31, 2025DALLAS, March 24, 2026 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (“AI”) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2025”) and full year (“FY 2025”) ended December 31, 2025 and provided an update on its ongoing activities related to the commercialization of its proprietary, AI-driven DeepView® System for burn indication. “2025 was a pivotal year for Spectral AI, highlighted by the submission of our De Novo 510(k) application to the U.S. Food and Drug Administration (“FDA”) of our DeepView...

Expands Board as Company Accelerates Growth in Solar Recycling and Critical Metals Recovery VIRGINIA CITY, Nev., March 24, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”), today announced its full year 2025 results, 2025 summary achievements, and our 2026 business outlook. “Last year marked a number of critical achievements that punctuated the turnaround from a junior mining opportunity into a validated, leading metals recovery company positioned for global growth, including final proof of our zero-landfill recycling concept from our demonstration facility, team-building, full permitting, final, first-of-its-kind engineered and tested designs, secured industrial scale facility and storage capacity and fully funded the facility and operations while also receiving direct investment from Marathon...

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter...